Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy

Diabetes and Metabolism

Volumn 34, Issue 6, 2008, Pages 587-594

  Cocchietto, M ^a   Zorzin, L ^a   Toffoli, B ^b   Candido, R ^c   Fabris, B ^b   Stebel, M ^d   Sava, G ^a,d  

^a Callerio Foundation   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Diabetic Centre ASSL Triestina   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

AGE; Animal model of diabetes; Biopolymers; Diabetes; Diabetic nephropathy; Microencapsulated lysozyme; Microspheres; Oral treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALGINIC ACID; CHITOSAN; LYSOZYME; MICROSPHERE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETOGENESIS; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG COATING; DRUG EFFICACY; DRUG UPTAKE; GLOMERULOPATHY; KIDNEY CIRCULATION; KIDNEY HYPERTROPHY; MALE; MICROALBUMINURIA; MICROENCAPSULATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SYSTEMIC CIRCULATION; WISTAR RAT;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CAPSULES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLYCOSURIA; GLYCOSYLATION END PRODUCTS, ADVANCED; MURAMIDASE; RATS; RATS, WISTAR;

EID: 57049100299     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2008.05.009     Document Type: Article

References (36)

1. Turk Z. Glycation and complication of diabetes. Diabetologia Croat 30 (2001) 49-54
2. Harvey J.N. Diabetic nephropathy. BMJ 325 (2002) 59-60
3. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C., Twigg S.M., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 (2002) 246-253
4. Hill J. Identifying and managing the complications of diabetes. Nurs Times 100 (2004) 40-44
5. Folan L.A., and Tuttle K.R. Diabetic nephropathy: implications for renal and cardiovascular outcomes. Minerva Med 95 (2004) 385-394
6. Thomas M.C., Forbes J.M., and Cooper M.E. Advanced glycation end products and diabetic nephropathy. Am J Ther 12 (2005) 562-572
7. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
9. Vlassara H. Advanced glycation end products and atherosclerosis. Ann Med 28 (1996) 419-426
10. Wautier J.L., and Guillausseau P.J. Diabetes, advanced glycation end products and vascular disease. Vasc Med 3 (1998) 131-137
11. Brownlee M., Vlassara N., and Cerami A. Nonenzymatic glycation and the pathogenesis of diabetic complications. Ann Intern Med 101 (1984) 527-537
12. Kennedy L., and Baynes J.W. Nonenzymatic glycosylation and chronic complications of diabetes: an overview. Diabetologia 27 (1984) 92-98
13. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., and Steffers M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Aca Sci U S A 91 (1994) 11704-11708
14. Chavakis T., Bierhaus A., and Nawroth P.P. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 6 (2004) 1219-1225
15. Wautier J.L., and Guillausseau P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27 (2001) 535-542
16. Vlassara H., and Palace M.R. Diabetes and advanced glycation end products. Intern Med J 251 (2002) 87-101
17. Basta G., Schmidt A.M., and De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63 (2004) 582-592
18. Bucala R., Vlassara H., and Cerami A. Advanced glycosylation end products. In: Harding J.J., and Crabbe M.J.C. (Eds). Posttranslational modification of proteins (1992), CRC Press Inc, Boca Raton, FL 53-59
19. Baynes J.W. AGEing growth factors: a role in diabetic vascular disease?. J Clin Invest 94 (1994) 2
20. Pertynska-Marczewska M., Kiriakidis S., Wait R., Beech J., Feldmann M., and Paleolog E.M. Advanced glycation end products upregulate angiogenic and proinflammatory cytokine production in human monocyte/macrophages. Cytokine 28 (2004) 35-47
21. Peppa M., He C., Hattori M., McEvoy R., Zheng F., and Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 52 (2003) 1441-1448
22. Chen Y., Yan S.S., Colgan J., Zhang H.P., Luban J., Schmidt A.M., et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol 173 (2004) 1399-1405
23. Mruthinti S., Buccafusco J.J., Hill W.D., Waller J.L., Jackson T.W., Zamrini E.Y., et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgG binding Abeta and RAGE peptides. Neurobiol Aging 25 (2004) 1023-1032
24. Sava G. Pharmacological aspects and therapeutic applications of lysozymes. In: Jollès P. (Ed). Lysozyme: Model enzymes in biochemistry and biology (1996), EXS 75 Birkhäuser Verlag, Basel 433-449
25. Jollès P. A possible physiological function of lysozyme. Biomedicine 25 (1976) 275-276
26. Pacor S., Giacomello E., Bergamo A., Gagliardi R., Cocchietto M., and Sava G. Cytofluorimetric analysis of gut-intraepithelial and mesenteric lymph node lymphocytes of tumour-bearing mice fed with egg-white lysozyme. Anticancer Res 16 (1996) 145-150
27. Zorzin L., Cocchietto M., Voinovich D., Marcuzzi A., Filipovic-Grcic J., Mulloni C., et al. Lysozyme-containing chitosan-coated alginate microspheres for oral immunisation. J Drug Del Sci Tech 16 (2006) 413-420
28. Allen P.M., Strydom D.J., and Unanue E.R. Processing of lysozyme by macrophages: identification of the determinant recognized by two T-cell hybridomas. Proc Nat Acad Sci U S A 81 (1984) 2489-2493
29. Mitsuhashi T., Li Y.M., Fishbane S., and Vlassara H. Depletion of reactive advanced glycation end products from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 100 (1997) 847-854
30. Zheng F., Cai W., Mitsuhashi T., and Vlassara H. Lysozyme enhances renal excretion of advanced glycation end products in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential age sequestration therapy for diabetic nephropathy?. Mol Med 7 (2001) 737-747
31. Li Y.M., Tan A.X., and Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1 (1995) 1057-1061
32. Sihna V.R., and Trehan A. Biodegradable microcapsules for protein delivery. J Control Release 90 (2003) 261-280
33. Vasir J.K., Tambwekar K., and Garg S. Bioadhesive microcapsules as a controlled drug delivery system. Int J Pharm 255 (2003) 13-32
34. Forbes J.M., Cooper M.E., Thallas V., Burns W.C., Thomas M.C., Brammar G.C., et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51 (2002) 3274-3282
35. Makita Z., Vlassara H., Cerami A., and Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267 (1992) 5133-5138
36. Eldridge J.H., Hammond C.J., Meulbroek J.A., Staas L.K., Gilley R.M., and Tice T.R. Controlled vaccine release in the gut-associated lymphoid tissue. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 11 (1990) 205-214